Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

APLMW

Apollomics (APLMW)

Apollomics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:APLMW
DateTimeSourceHeadlineSymbolCompany
06/04/20247:00AMGlobeNewswire Inc.Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:APLMWApollomics Inc
05/30/20243:15PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:APLMWApollomics Inc
05/29/202411:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:APLMWApollomics Inc
05/29/20244:12PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:APLMWApollomics Inc
05/29/20247:00AMGlobeNewswire Inc.Apollomics Announces Presentation at the 2024 BIO International ConventionNASDAQ:APLMWApollomics Inc
05/24/20244:03PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:APLMWApollomics Inc
05/24/20243:58PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:APLMWApollomics Inc
05/20/20243:32PMEdgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:APLMWApollomics Inc
05/20/20243:15PMEdgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:APLMWApollomics Inc
05/20/20243:15PMEdgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:APLMWApollomics Inc
05/08/20243:05PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:APLMWApollomics Inc
05/08/20243:05PMGlobeNewswire Inc.Apollomics Announces Private Placement Financing and Addition to Board of DirectorsNASDAQ:APLMWApollomics Inc
04/25/20247:30AMGlobeNewswire Inc.Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion GeneNASDAQ:APLMWApollomics Inc
04/10/20246:00AMGlobeNewswire Inc.Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual MeetingNASDAQ:APLMWApollomics Inc
04/02/20247:00AMGlobeNewswire Inc.Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual MeetingNASDAQ:APLMWApollomics Inc
03/28/20246:00AMGlobeNewswire Inc.Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial ResultsNASDAQ:APLMWApollomics Inc
03/26/20247:00AMGlobeNewswire Inc.Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024NASDAQ:APLMWApollomics Inc
03/04/20246:00AMGlobeNewswire Inc.Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial OfficerNASDAQ:APLMWApollomics Inc
02/07/20246:00AMGlobeNewswire Inc.Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:APLMWApollomics Inc
01/19/20243:15PMGlobeNewswire Inc.Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyNASDAQ:APLMWApollomics Inc
01/17/20243:30PMGlobeNewswire Inc.Apollomics to Participate in a Fireside Chat at the B. Riley Securities’ 2024 Virtual Oncology ConferenceNASDAQ:APLMWApollomics Inc
01/03/20246:00AMGlobeNewswire Inc.Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid LeukemiaNASDAQ:APLMWApollomics Inc
01/02/20243:30PMGlobeNewswire Inc.Apollomics to Present at the 2024 Biotech ShowcaseNASDAQ:APLMWApollomics Inc
12/04/20236:00AMGlobeNewswire Inc.Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping MutationNASDAQ:APLMWApollomics Inc
11/29/20236:30AMGlobeNewswire Inc.Apollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual ConferenceNASDAQ:APLMWApollomics Inc
11/28/20236:00AMGlobeNewswire Inc.Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)NASDAQ:APLMWApollomics Inc
11/16/20237:30AMGlobeNewswire Inc.Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung CancerNASDAQ:APLMWApollomics Inc
10/31/20237:30AMGlobeNewswire Inc.Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET DysregulationNASDAQ:APLMWApollomics Inc
10/26/20237:50AMGlobeNewswire Inc.Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET FusionNASDAQ:APLMWApollomics Inc
10/23/20237:30AMGlobeNewswire Inc.Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75%NASDAQ:APLMWApollomics Inc
 Showing the most relevant articles for your search:NASDAQ:APLMW